WEST LAFAYETTE, Ind., May 19, 2014 (GLOBE NEWSWIRE) -- Endocyte, Inc. (Nasdaq:ECYT) a biopharmaceutical company and leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy in cancer and other serious diseases, today announced that two poster presentations featuring Endocyte’s SMDC EC1456 and companion imaging agent etarfolatide will be presented at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO) being held May 30 - June 3, 2014, in Chicago.
Help employers find you! Check out all the jobs and post your resume.
